Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Environmental swabs reveal hidden avian viral diversity

5

Mar 2026

Environmental swabs reveal hidden avian viral diversity

Scientists at Duke-NUS Medical School have found that viruses circulating in live poultry markets can be detected more effectively by sampling the surrounding environment than by testing individual birds. The study, published in Nature Communications, shows that environmental sampling can uncover a broader range of poultry viruses-including highly pathogenic avian influenza strains that traditional surveillance may miss.

Wearable sensors as a tool for MS monitoring

4

Mar 2026

Wearable sensors as a tool for MS monitoring

Wearable sensors may help identify people with multiple sclerosis (MS) who are more likely to have worsening disability and loss of brain volume, according to a study published on March 4th, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

AI pinpoints why vaccine responses vary globally

4

Mar 2026

AI pinpoints why vaccine responses vary globally

How people with compromised immune systems respond to vaccines is an important area of immunological research. A new study led by York University found that not only could machine-learning models accurately pinpoint differences in healthy controls and those living with HIV, but also found outliers in both groups that provide fascinating glimpses into the complex nature of the immune system and what personalized medicine could look like in the future, accounting for variables such as age, comorbidities and genetics.

Novel gene regulation therapy passes key clinical milestone

4

Mar 2026

Novel gene regulation therapy passes key clinical milestone

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective.

Mapping the year-one weight trajectory after stopping GLP-1s

4

Mar 2026

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.